All stock lists
Clover Health Investments, Corp. /De (NASDAQ:CLOV)
US · Delayed Price · Currency is USD
Healthcare · Medical - Healthcare Plans
4.56-0.04 (-0.87%)
Market cap
$2.42B
Health Score
Analyst consensus
Listed since
Jun 12, 2020
Website
Insider Score
––Not scored
CLOV Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
CLOV analyst forecast
CLOV analyst consensus
Hold1 ratings
Buy 0 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CLOV 12-month price target
No published price targets in the last 12 months.
Best analysts covering CLOV
- Canaccord Genuity33%success rate · 3 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CLOV analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | UBS | Neutral | — | — | Reiterated | 2026-08-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-07-21 |
| — | UBS | Neutral | — | — | Reiterated | 2026-06-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-06-04 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-03-20 |
| — | Leerink Partners | Market Perform | — | — | Reiterated | 2026-03-05 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-01-20 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-11-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-08-07 |
| — | UBS | Neutral | — | — | Reiterated | 2025-08-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-03-03 |
| — | Citigroup | Neutral | — | — | Reiterated | 2023-08-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2023-03-06 |
| — | Credit Suisse | Underperform | — | — | Reiterated | 2023-03-06 |
| — | Citigroup | Neutral | — | — | Reiterated | 2022-11-16 |
| — | SVB Leerink | Market Perform | — | — | Reiterated | 2022-11-08 |
| — | Citigroup | Neutral | — | — | Reiterated | 2022-08-09 |
| — | Credit Suisse | Underperform | — | — | Reiterated | 2022-08-09 |
| — | SVB Leerink | Market Perform | — | — | Reiterated | 2022-05-10 |
| — | SVB Leerink | Market Perform | — | — | Reiterated | 2022-02-25 |
| — | Cowen & Co. | Market Perform | — | — | Upgraded | 2022-02-02 |
| — | Credit Suisse | Underperform | — | — | Downgraded | 2022-01-07 |
| — | Credit Suisse | Neutral | — | — | Reiterated | 2021-11-15 |
| — | JP Morgan | Underweight | — | — | Downgraded | 2021-07-12 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2021-06-10 |
| — | Credit Suisse | Neutral | — | — | Reiterated | 2021-05-19 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2021-05-17 |
CLOV earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | -0.10 | -0.05 | $467.1M | $487.7M |
| 2026-05-06 | 0.07 | 0.07 | $714.9M | $749.2M |
| 2026-08-05 | 0.04 | 0.05 | $728.3M | $743.2M |
| 2026-11-04 | -0.00 | 0.00 | $740.3M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.